The 2.4 billion Euro European Innovative Health Initiative (IHI) aims for more cooperation across sector boundaries. Parties in Pharma, Medtech, BioTech, AI and imaging will work together with patients. Finding the right partners for your IHI proposal can be challenging. With more than 10 years of experience, ttopstart can help you.
IHI challenges
There is an urgent need for an innovative, more integrated approach to health research and healthcare. Future breakthroughs in medical science will involve cross-sectoral discoveries, such as medical device/drug combinations or diagnostics based on artificial intelligence.
The number of participating sector organisations in IHI is, therefore, larger and broader than in IMI. In addition to the main IMI partner EFPIA (European Federation of Pharmaceutical Industries and Associations) new partners Vaccines Europe, COCIR (medical imaging, radiotherapy, health ICT and electromedical industries), EuropaBio (biotechnology industry) and MedTech Europe (medical technology industry) will co-fund the programme.
Need help? Please contact our IHI expert Marc Derieppe.
How can we help you
We strongly believe in IHI’s strategy to further cross-sectoral innovations, which in the end will have a real and sustainable impact on patient and patient care. But how do you find the right consortium partners in these sectors that are still often isolated? How do you ensure that you are at the right table on time? How do you align your goals with those of others?’ ttopstart has more than 12 years of experience in bringing together partners, in particular in IMI and this year iHI projects. We developed a set of ‘best practices’ to keep all your consortium partners engaged and focused on the real impact for patients. Have a look at our client stories
Topics
The end of June, IHI has opened call 8 for application. It is a two-stage call with topics on cardiovascular disease, osteoarthritis, regulatory sandboxes, and patient-centred endpoints.
Topics:
- City-based approach to reducing cardiovascular mortality in Europe
- Novel endpoints for osteoarthritis (OA) by applying big data analytics
- Modelling regulatory sandbox mechanisms and enabling their deployment to support breakthrough innovation
- Patient-centred clinical-study endpoints derived using digital health technologies
Related news
IHI call 8 open for applications
IHI call 8 open for applicationsThe Innovative Health Initiative (IHI) has opened call 8 for application. It is a two-stage call with topics on cardiovascular disease, osteoarthritis, regulatory sandboxes, and patient-centred endpoints.The maximum financial...
IHI launches new funding round: calls 6 and 7
IHI launches new funding round: calls 6 and 7The Innovative Health Initiative (IHI) has launched two new calls for proposals, IHI calls 6 and 7, addressing a wide range of challenges in health research and innovation.Approximately EUR 120 million in funding from IHI...
Registration open for IHI Call Days calls 6 and 7
Registration is open for IHI Call Days calls 6 and 7Save the date!Registration is now open for the IHI Call Days featuring calls 6 and 7, accessible through the IHI Call Days platform. Information sessions Information sessions are scheduled from January 10 to 16,...
IHI launched new draft topics for calls 6 and 7
IHI has published draft topics for IHI calls 6 and 7The draft texts of the topics planned for inclusion in IHI's next call for proposals are now available online. The following topics are currently under review for potential inclusion in the upcoming IHI calls for...
Client stories
PRECIOUS
is a multi-national project and aims at scaling-up biodegradable nanomedicines for multimodal precision cancer immunotherapy.
OPTIMA
aims to improve treatment for patients with cancer through artificial intelligence.
Immune-Image
is an IMI-funded project that aims to set up a sustainable and flexible platform for molecular imaging of immune cell dynamics using a broad range of novel tracer strategies.